8-K: Athira Pharma Reports Q3 2025 Results, Explores Strategic Options

Athira Pharma reported its third-quarter 2025 financial results, highlighting progress in its ATH-1105 clinical program and ongoing exploration of strategic alternatives to maximize stockholder value.

Summary

• Athira Pharma reported financial results for the quarter ended September 30, 2025, and provided business updates.
• The company is actively exploring strategic alternatives to maximize stockholder value, engaging Cantor Fitzgerald & Co. as an advisor following the Phase 2/3 LIFT-AD clinical trial results in September 2024.
• Positive results from the Phase 1 clinical trial of ATH-1105 in healthy volunteers were presented, demonstrating a favorable safety and tolerability profile, dose-proportional pharmacokinetics, and central nervous system (CNS) penetration.
• ATH-1105 is a novel, orally available, brain-penetrant small molecule drug candidate designed to modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's, and Parkinson's disease, currently in clinical development for ALS.
• The Phase 1 study (NCT 06432647) was completed in November 2024.
• Preclinical evidence supports ATH-1105's potential, showing statistically significant improvements in nerve and motor function, biomarkers of inflammation and neurodegeneration, and survival in various ALS models.
• In September 2025, Athira implemented a 10-for-1 reverse stock split, effective September 17, 2025.
• Cash, cash equivalents, and investments were $25.2 million as of September 30, 2025, a decrease from $51.3 million as of December 31, 2024.
• Net cash used in operations for the nine months ended September 30, 2025, was $26.3 million, significantly lower than $71.2 million for the same period in 2024.
• Research and Development (R&D) expenses decreased to $2.8 million for Q3 2025, compared to $17.9 million for Q3 2024.
• General and Administrative (G&A) expenses decreased to $4.1 million for Q3 2025, compared to $7.6 million for Q3 2024.
• Net loss was $6.6 million, or $1.68 per share, for Q3 2025, a substantial improvement from a net loss of $28.7 million, or $7.46 per share, for Q3 2024.

Sentiment

Score: 6

Explanation: While financial metrics show significant improvement in cost control and reduced losses, the underlying reason (strategic alternatives, post-LIFT-AD failure, reverse stock split) indicates challenges. The positive Phase 1 data for ATH-1105 is a strong point, but it's still early stage for ALS. The overall sentiment is cautiously optimistic due to cost cutting and new pipeline focus, but tempered by the strategic uncertainty.

Positives

• ATH-1105 Phase 1 clinical trial demonstrated a favorable safety and tolerability profile in healthy volunteers.
• ATH-1105 showed dose-proportional pharmacokinetics and central nervous system (CNS) penetration, supporting continued clinical development.
• Preclinical models of ALS for ATH-1105 have shown consistent and robust beneficial effects, including improvements in nerve and motor function, biomarkers, and survival.
• Research and Development expenses significantly decreased to $2.8 million for Q3 2025 from $17.9 million for Q3 2024.
• General and Administrative expenses significantly decreased to $4.1 million for Q3 2025 from $7.6 million for Q3 2024.
• Net loss substantially improved to $6.6 million for Q3 2025 from $28.7 million for Q3 2024.
• Net loss per share improved to $1.68 for Q3 2025 from $7.46 for Q3 2024 (on a split-adjusted basis).
• Net cash used in operations for the nine months ended September 30, 2025, was $26.3 million, a significant reduction from $71.2 million for the same period in 2024.

Negatives

• Cash, cash equivalents, and investments decreased to $25.2 million as of September 30, 2025, from $51.3 million as of December 31, 2024, indicating ongoing cash burn.
• The company continues to incur a net loss, totaling $6.6 million for the quarter ended September 30, 2025.
• The exploration of strategic alternatives, following the topline results of the Phase 2/3 LIFT-AD clinical trial, suggests a period of uncertainty and potential restructuring.
• The 10-for-1 reverse stock split typically indicates a low share price and an effort to maintain listing compliance, which can be perceived negatively by investors.

Risks

• Data from preclinical and clinical trials may not support the safety, efficacy, and tolerability of drug candidates.
• Development of drug candidates may cease or be delayed.
• Regulatory authorities could object to protocols, amendments, and other submissions.
• Future potential regulatory milestones for drug candidates may be insufficient to support regulatory submissions or approval.
• Trials may not be sufficiently powered to meet planned endpoints.
• Inability to recruit sufficient patients for clinical trials.
• The outcome of legal proceedings that may in the future be instituted against the company, its directors, and officers.
• Possible negative interactions of drug candidates with other treatments.
• FDA regulatory delays and uncertainty, including new policies, changes in leadership of federal agencies, staff layoffs, budget cuts, and changes in drug pricing controls.
• Assumptions regarding financial condition and the sufficiency of cash, cash equivalents, and investments to fund planned operations may be incorrect.
• Adverse conditions in the general domestic and global economic markets, including as a result of tariffs.
• The impact of competition.
• The impact of drug candidate development and clinical activities on operating expenses.
• The impact of new or changing laws and regulations.
• Risks related to the exploration of strategic alternatives.

Future Outlook

The company plans to advance the ATH-1105 program into ALS patients, either independently or in conjunction with a partner, based on promising Phase 1 data and preclinical evidence. They continue to explore strategic alternatives focused on maximizing stockholder value.

Management Comments

• "We continue to explore strategic alternatives focusing on maximizing stockholder value and remain encouraged by the promising data to-date supporting the continued development of ATH-1105 as a potential therapy for ALS."
• "We were especially pleased to present results from the Phase 1 study of ATH-1105 that continue to demonstrate favorable safety and tolerability in healthy volunteers and dose proportional pharmacokinetics and CNS penetration."
• "We look forward to an opportunity to advance this program into ALS patients, in order to move us one step closer to bringing a potential novel therapy to patients desperately in need of an effective treatment option."

Industry Context

Athira operates in the highly competitive and high-risk biopharmaceutical sector, specifically targeting neurodegenerative diseases. The focus on the HGF system represents a specific therapeutic approach. The exploration of strategic alternatives is a common occurrence for clinical-stage companies, particularly after significant trial results, as they seek funding or partnerships to advance their pipeline. The substantial reduction in R&D and G&A spending suggests a strategic pivot and cost-cutting measures, likely in response to prior clinical trial outcomes and the need to extend operational runway while focusing on the most promising assets.

Corporate Governance

Stakeholder Impact

• Shareholders face potential for increased share price due to the reverse stock split, but also uncertainty due to the ongoing exploration of strategic alternatives. The positive early clinical data for ATH-1105 offers long-term potential.
• Employees may experience uncertainty related to the exploration of strategic alternatives, which could lead to restructuring or changes in company direction.
• Patients with ALS may benefit from the continued development of ATH-1105 as a potential novel treatment option, offering hope for an unmet medical need.

Next Steps

• Advance the ATH-1105 program into clinical trials for ALS patients.
• Continue exploring strategic alternatives to maximize stockholder value, potentially including partnerships or other corporate transactions.
• Further evaluate ATH-1105's potential as a novel therapy for ALS.

Key Dates

Recommendation

The company has significantly cut costs and reduced its net loss, which is a positive step towards financial stability. The Phase 1 data for ATH-1105 is encouraging, showing a favorable safety profile and CNS penetration, supporting its potential in ALS. However, the company is still in a clinical stage with a significant cash burn, albeit reduced, and is actively exploring strategic alternatives following a prior trial failure (LIFT-AD). This indicates ongoing uncertainty regarding its long-term strategy and funding. While the cost controls and new pipeline focus are positive, the early stage of ATH-1105 and the strategic uncertainty warrant a 'hold' rather than a 'buy' or 'sell' until more clarity emerges on the strategic direction and further clinical progress.

Keywords

Athira Pharma, ATHA, biopharmaceutical, neurodegeneration, ALS, Alzheimer's disease, Parkinson's disease, ATH-1105, Phase 1 clinical trial, financial results, strategic alternatives, reverse stock split, Q3 2025, SEC filing, 8-K, clinical stage, HGF system, neuronal health, pharmacokinetics, CNS penetration